143 related articles for article (PubMed ID: 17886336)
1. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome.
Wong F; Moore K; Dingemanse J; Jalan R
Hepatology; 2008 Jan; 47(1):160-8. PubMed ID: 17886336
[TBL] [Abstract][Full Text] [Related]
2. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
3. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
Chin A; Radhakrishnan J; Fornell L; John E
J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
5. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
6. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock.
Chin A; Radhakrishnan J; Fornell L; John E
J Pediatr Surg; 2002 Mar; 37(3):482-7. PubMed ID: 11877672
[TBL] [Abstract][Full Text] [Related]
7. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
Duvoux C; Zanditenas D; Hézode C; Chauvat A; Monin JL; Roudot-Thoraval F; Mallat A; Dhumeaux D
Hepatology; 2002 Aug; 36(2):374-80. PubMed ID: 12143045
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
[TBL] [Abstract][Full Text] [Related]
9. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
10. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
11. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
13. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.
Urbanowicz W; Sogni P; Moreau R; Tazi KA; Barriere E; Poirel O; Martin A; Guimont MC; Cazals-Hatem D; Lebrec D
Gut; 2004 Dec; 53(12):1844-9. PubMed ID: 15542526
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
[TBL] [Abstract][Full Text] [Related]
15. The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock.
Fenhammar J; Andersson A; Frithiof R; Forestier J; Weitzberg E; Sollevi A; Hjelmqvist H
Acta Anaesthesiol Scand; 2008 Nov; 52(10):1385-93. PubMed ID: 19025532
[TBL] [Abstract][Full Text] [Related]
16. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
[TBL] [Abstract][Full Text] [Related]
17. Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep.
Kuklin VN; Kirov MY; Evgenov OV; Sovershaev MA; Sjöberg J; Kirova SS; Bjertnaes LJ
Crit Care Med; 2004 Mar; 32(3):766-73. PubMed ID: 15090960
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
[TBL] [Abstract][Full Text] [Related]
20. Effects of endothelin receptor antagonism on acute lung injury induced by chlorine gas.
Wang J; Oldner A; Winskog C; Edston E; Walther SM
Crit Care Med; 2006 Jun; 34(6):1731-7. PubMed ID: 16625121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
